AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals and Merck Sign Collaboration for Clinical Drug Response Predicition

AVEO Pharmaceuticals and Merck Sign Collaboration for Clinical Drug Response Predicition

November 2, 2005

Agreement Marks First Application of Novel Platform for Predicting Clinical Response Based on Genetic Profiles

Zalicus

CombinatoRx, Incorporated Announces Pricing of Its Initial Public Offering

CombinatoRx, Incorporated Announces Pricing of Its Initial Public Offering

November 9, 2005

BOSTON, Nov 09, 2005 (BUSINESS WIRE) -- CombinatoRx, Incorporated (Nasdaq: CRXX) today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by CombinatoRx. In addition, CombinatoRx has granted the underwriters an option to purchase up to an additional 900,000 shares to cover over-allotments, if any.

Affinnova, Inc.

Affinnova Names Waleed Al-Atraqchi as CEO and President

Affinnova Names Waleed Al-Atraqchi as CEO and President

November 14, 2005

Seasoned consumer packaged goods and marketing services executive to lead company

Black Duck Software, Inc.

Black Duck Expands Advisory Board With Prominent Industry Executives and Academics

Black Duck Expands Advisory Board With Prominent Industry Executives and Academics

December 5, 2005

WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 5, 2005--Black Duck Software, the leading provider of software compliance management solutions, today announced that it has expanded its corporate advisory board with seven prominent industry executives and academics. Alex Aiken, Dave Bernstein, Dan Bricklin, Dave Flaschen, Ed Roberts, Jothy Rosenberg and Arthur Tyde have joined Larry Rosen, the noted open source and intellectual property attorney, as industry advisors.

EXACT Sciences

EXACT Sciences and Apogent Discoveries Announce Patent Licensing Agreement

EXACT Sciences and Apogent Discoveries Announce Patent Licensing Agreement

December 13, 2002

MAYNARD - December 13, 2002 -- EXACT Sciences Corporation and Apogent Discoveries announced today that they have executed a licensing agreement regarding certain patents owned by Apogent relating to its Acrydite™ technologies. The license provides EXACT Sciences, and its partners, with the ability to manufacture and use Acrydite in EXACT Sciences' PreGen-Plus™ assay. PreGen-Plus™ is EXACT Sciences' proprietary fecal DNA assay to detect colorectal cancer in the average-risk population. Terms of the agreement were not disclosed.

CGI Pharmaceuticals, Inc.

Cellular Genomics Establishes Research Collaboration With Lilly

Cellular Genomics Establishes Research Collaboration With Lilly

December 17, 2003

BRANFORD, Conn., Dec. 17 /PRNewswire/ -- Cellular Genomics Inc. (CGI), a chemical genetics based biopharmaceutical company, today announced that it has entered into a research collaboration with Eli Lilly and Company, under which CGI will apply its chemical genetics Analog Sensitive Kinase Allele (ASKA) technology to the study of kinase drug targets selected by Lilly.

Zalicus

CombinatoRx, Incorporated Files Registration Statement for Proposed Initial Public Offering

CombinatoRx, Incorporated Files Registration Statement for Proposed Initial Public Offering

December 13, 2004

BOSTON, Dec. 13 /PRNewswire/ -- CombinatoRx, Incorporated announced today that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. All of the shares of common stock will be offered by the Company. SG Cowen & Co., LLC is acting as sole book-running manager, Pacific Growth Equities, LLC is acting as co-lead manager, and SunTrust Robinson Humphrey and A.G. Edwards are acting as co-managers for the proposed offering.

Hypnion, Inc.

Hypnion, Inc. Raises $20.1 Million in Extended Series B Financing

Hypnion, Inc. Raises $20.1 Million in Extended Series B Financing

December 19, 2005

Funds Will Advance Clinical Development of Novel Therapies for Insomnia

Epitome Biosystems

Epitome Biosystems to Develop Biomarker Assay Panels for Bristol-Myers Squibb

Epitome Biosystems to Develop Biomarker Assay Panels for Bristol-Myers Squibb

January 4, 2006

WALTHAM, Mass., Jan. 4 /PRNewswire/ -- Epitome Biosystems announced today that it has signed a technology access and product development agreement with Bristol-Myers Squibb Company (NYSE: BMY) for use of Epitome's proprietary EpiTag(TM) protein measurement platform. Epitome will develop custom antibody arrays for quantitative and high throughput measurement of proteins specified by Bristol-Myers Squibb to accelerate introduction of newly discovered biomarkers into clinical development programs.

Interactive Supercomputing Corporation

Interactive Supercomputing Secures VC Funding

Interactive Supercomputing Secures VC Funding

January 17, 2006

Funding to accelerate sales and marketing and R&D efforts

WALTHAM, Mass., Jan. 17 /PRNewswire/ -- On the heels of a successful product launch last quarter, Interactive Supercomputing, Inc. (ISC) today announced it secured a $4.5 million Series-A investment. Flagship Ventures led the round, joined by Rock Maple Ventures and CommonAngels, a network of private investors and limited partners.